Objective To evaluate the perception of patients with Parkinson's disease (PD) regarding dyskinesia.
Design Multicentre survey.
Setting Tertiary referral centres.
Patients Patients with PD participated in a survey: those not on dopaminergic medications (group I), those on dopaminergic medications without dyskinesia (group II) and those on dopaminergic medications with dyskinesia (group III).
Intervention After a short standardised description and explanation of dyskinesia was provided, patients were asked about the nature and source of prior knowledge of dyskinesia. They were then asked about their perceptions of dyskinesia. Patients in group III were also asked about the duration, the severity of dyskinesia and whether their perception of this problem had changed since its appearance.
Main outcome measures Level of concern regarding dyskinesia and whether their perception of dyskinesia would have changed their preference of treatment.
Results 259 PD patients completed the survey (group I, 52; group II, 102; group III, 105). Patients with dyskinesia were significantly less concerned about dyskinesia than patients without dyskinesia and were more likely to choose dyskinesia over being parkinsonian. Patients who required fewer changes in medications because of dyskinesia were more likely to choose dyskinesia over parkinsonism.
Conclusion Patients with PD experiencing dyskinesia are less likely to be concerned about dyskinesia and more likely to prefer dyskinesia over parkinsonian symptoms than patients without dyskinesia.
- Parkinson's disease
- treatment initiation
- dopamine agonists
- quality of life
Statistics from Altmetric.com
Funding SWH has received financial support for research and speaker fees from St. Jude Medical Neuromodulation Division, UCB Pharma and Teva Neuroscience. GMA has nothing to disclose; TA has nothing to disclose; SHF has received financial support for research, consultancy and speaker fees from Novartis, Kyowa, Teva, Eisai, GW Bayer, Prestwick, GlaxoSmithKline; and AEL has received consulting fees or honoraria from Boerhinger-Ingelheim, Ceregene, Eisai, Medtronic, Novartis, Prestwick, Serono, Solvay, Taro and Teva.
Competing interests None.
Ethics approval This study was conducted with the approval of the institutional review boards of the University of Toronto and the Medical College of Wisconsin.
Provenance and peer review Not commissioned; externally peer reviewed.